EGFR and non-small cell lung carcinoma: A total of 611 NSCLC patients who harbored information on EGFR mutation status (304 EGFR‐mutated patients and 307 EGFR wild‐type patients) and developed brain metastasis in their disease progression were identified for the present analysis.